S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Copper More Critical than Lithium? (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Copper More Critical than Lithium? (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Copper More Critical than Lithium? (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Copper More Critical than Lithium? (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
NASDAQ:BNTC

Benitec Biopharma - BNTC Stock Forecast, Price & News

$0.84
+0.05 (+6.37%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.77
$0.85
50-Day Range
$0.74
$1.54
52-Week Range
$0.67
$4.78
Volume
208,719 shs
Average Volume
942,064 shs
Market Capitalization
$6.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Benitec Biopharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,097.6% Upside
$10.00 Price Target
Short Interest
Healthy
1.47% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.89) to ($0.87) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

BNTC stock logo

About Benitec Biopharma (NASDAQ:BNTC) Stock

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

Benitec Biopharma Trading Up 7.0 %

Benitec Biopharma stock opened at $0.84 on Wednesday. The firm has a market cap of $6.82 million, a price-to-earnings ratio of 0.00 and a beta of 1.22. Benitec Biopharma has a 1 year low of $0.67 and a 1 year high of $4.78. The firm's 50 day moving average price is $0.97 and its two-hundred day moving average price is $1.65. The company has a debt-to-equity ratio of 0.08, a quick ratio of 4.63 and a current ratio of 4.63.

Benitec Biopharma (NASDAQ:BNTC - Get Rating) last issued its earnings results on Monday, May 16th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $0.04. The company had revenue of $0.05 million during the quarter. On average, research analysts predict that Benitec Biopharma will post -1.89 EPS for the current fiscal year.

Receive BNTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Benitec Biopharma and its competitors with MarketBeat's FREE daily newsletter.

BNTC Stock News Headlines

Benitec Biopharma Shares Surge 119%, to $1.62
Benitec Biopharma Discloses Q2 2022 Financial Results
/C O R R E C T I O N from Source -- Norra Metals Corp./
Benitec Biopharma Discloses Q1 2022 Financial Results
Benitec Biopharma Ltd. ADR
See More Headlines
Receive BNTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Benitec Biopharma and its competitors with MarketBeat's FREE daily newsletter.

BNTC Company Calendar

Last Earnings
5/16/2022
Today
8/10/2022
Next Earnings (Estimated)
9/19/2022
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BNTC
Employees
14
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+1,097.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-13,880,000.00
Pretax Margin
-22,858.67%

Debt

Sales & Book Value

Annual Sales
$60,000.00
Book Value
$2.55 per share

Miscellaneous

Free Float
7,960,000
Market Cap
$6.82 million
Optionable
Not Optionable
Beta
1.22

Key Executives

  • Dr. Jerel A. Banks M.D. (Age 47)
    Ph.D., CEO & Exec. Chairman
    Comp: $697.69k
  • Ms. Megan Joan Boston BComm (Age 50)
    CA, Dip., GAICD, Exec. Director
    Comp: $401.7k
  • Mr. Bryan Dulhunty
    Chief Financial Officer
  • Dr. Michael Graham
    Head of Discovery & Founding Scientist
  • Dr. Craig Lewis
    Chief Medical Adviser
  • Dr. Claudia Kloth
    Sr. VP of Manufacturing













BNTC Stock - Frequently Asked Questions

Should I buy or sell Benitec Biopharma stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Benitec Biopharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BNTC shares.
View BNTC analyst ratings
or view top-rated stocks.

What is Benitec Biopharma's stock price forecast for 2022?

1 brokers have issued 1 year target prices for Benitec Biopharma's stock. Their BNTC share price forecasts range from $10.00 to $10.00. On average, they expect the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 1,097.6% from the stock's current price.
View analysts price targets for BNTC
or view top-rated stocks among Wall Street analysts.

How has Benitec Biopharma's stock performed in 2022?

Benitec Biopharma's stock was trading at $2.62 at the beginning of 2022. Since then, BNTC shares have decreased by 68.1% and is now trading at $0.8350.
View the best growth stocks for 2022 here
.

When is Benitec Biopharma's next earnings date?

Benitec Biopharma is scheduled to release its next quarterly earnings announcement on Monday, September 19th 2022.
View our BNTC earnings forecast
.

How were Benitec Biopharma's earnings last quarter?

Benitec Biopharma Inc. (NASDAQ:BNTC) released its quarterly earnings results on Monday, May, 16th. The biotechnology company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.04. The biotechnology company had revenue of $0.05 million for the quarter.

What other stocks do shareholders of Benitec Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Benitec Biopharma investors own include Amarin (AMRN), Pfizer (PFE), Amicus Therapeutics (FOLD), Sorrento Therapeutics (SRNE), Arbutus Biopharma (ABUS), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL), BioLineRx (BLRX) and CRISPR Therapeutics (CRSP).

When did Benitec Biopharma IPO?

(BNTC) raised $0 in an initial public offering on Thursday, August 6th 2015. The company issued 0 shares at $0.00 per share. BMO Capital Markets and Maxim Group LLC acted as the underwriters for the IPO and Roth Capital Partners was co-manager.

What is Benitec Biopharma's stock symbol?

Benitec Biopharma trades on the NASDAQ under the ticker symbol "BNTC."

How do I buy shares of Benitec Biopharma?

Shares of BNTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Benitec Biopharma's stock price today?

One share of BNTC stock can currently be purchased for approximately $0.84.

How much money does Benitec Biopharma make?

Benitec Biopharma (NASDAQ:BNTC) has a market capitalization of $6.82 million and generates $60,000.00 in revenue each year. The biotechnology company earns $-13,880,000.00 in net income (profit) each year or ($179.01) on an earnings per share basis.

How many employees does Benitec Biopharma have?

Benitec Biopharma employs 14 workers across the globe.

How can I contact Benitec Biopharma?

Benitec Biopharma's mailing address is Level 14 114 William St, Melbourne C3, 3000. The official website for the company is www.benitec.com. The biotechnology company can be reached via phone at 510-780-0819, via email at jmorakis@mgroupsc.com, or via fax at 61 (0)3 9966-9923.

This page (NASDAQ:BNTC) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.